Ocular delivery of flurbiprofen based on Eudragit® E-flurbiprofen complex dispersed in aqueous solution: Preparation, characterization, in vitro corneal penetration, and ocular irritation

Journal of Pharmaceutical Sciences

Volumn 103, Issue 12, 2014, Pages 3859-3868

  Quinteros, Daniela Alejandra ^a   Tártara, Luis Ignacio ^a   Palma, Santiago Daniel ^a   Manzo, Ruben Hilario ^a   Allemandi, Daniel Alberto ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Complex; Controlled release; Eudragit; Flurbiprofen; Ophthalmic solution; Permeability; Polymeric drug delivery systems

Indexed keywords

EUDRAGIT; FLURBIPROFEN; DRUG CARRIER; EUDRAGIT-E; EYE DROPS; METHACRYLIC ACID METHYL ESTER;

ANIMAL CELL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORNEA PERMEABILITY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; EXPERIMENTAL RABBIT; EYE IRRITATION; IN VITRO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SOLID STATE; SURFACE TENSION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CORNEA; DRUG EFFECTS; DRUG STABILITY; MEDICINAL CHEMISTRY; PERMEABILITY; PROCEDURES; RABBIT;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CORNEA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FLURBIPROFEN; METHYLMETHACRYLATES; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; PERMEABILITY; RABBITS;

EID: 84914810161     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24153     Document Type: Article

References (39)

1. Sahoo S, Sanjeeb K, Fahima D, Krishnakumar S. 2008. Nanotechnology in ocular drug delivery. Drug Discov Today 13(3-4):144-151.
2. Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. 2009. Nanomedicines for ocular NSAIDs: Safety on drug delivery. Nanomedicine 5:394-401.
3. Ahuja M, Dhake AS, Sharma SK, Majumdar, DK. 2008. Topical ocular delivery of NSAIDs. AAPS J 10:229-241.
4. Radwan MA, Aboul-Enein HY. 2004. In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide-co-glycolide) nanoparticles in rats. Chirality 16:119-125.
5. Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM. 2009. Lipid nanoparticles for transdermal delivery of flurbiprofen: Formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis 8:1-15.
6. Shaikh MY, Mars JS, Heaven CJ. 2003. Prednisolone and flurbiprofen drops to maintain mydriasis during phacoemulsification cataract surgery. J Cataract Refract Surg 29:2372-2377.
7. Stephen JK, Allan JF, Lee M. 2010. Jampol nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 55(2):108-133.
8. Congdon NG, Schein OD, Kulajta PV, Lubomski LH, Gilbert D, Katz J. 2001. Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. J Cataract Refract Surg 27:622-631. DOI: 10.1111/j.1574-6968.2012.02626.x
9. Araújo J, Vega E, Lopes C, Egea MA, Garcia ML, Souto EB. 2009. Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloid Surf B 72:48-56.
10. Lemkes TL, Williams DA, Eds. 1995. Foye's principles of medicinal chemistry, Vol 4. Lalvem, Pennsylvania: Lea & Febiger, pp 948-959.
11. Hansch C, Leo A, Hoekman D. 1995. Exploring QSAR, hydrophobic, electronic and steric constants; ACS Professional Reference Book. Washington, DC: American Chemical Society.
12. Ocufen. 2013. Accessed on 10 April 2013, at: http://www.accessdata.fda.gov/drugsatfda docs/label/2003/19404scp020-ocufen-lbl.pdf.
13. Quinteros DA, Ramirez Rigo MV, Jimenez Kairuz AF, Olivera ME, Manzo RH, Allemandi DA. 2008. Interaction between a cationic polymethacrylates (Eudragit E100) and anionic drugs. Eur J Pharm Sci 33:72-79.
14. Eudragit® EPO. 2012. Accessed on 1 October 2012, at: http://eudragit.evonik.com/product/eudragit/Documents/evonik-brochure-eudragit-product.pdf.
15. Quinteros DA, Allemandi DA, Manzo RH. 2012. Equilibrium and release properties of aqueous dispersions of nonsteroidal antiinflammatory drugs complexed with polyelectrolyte Eudragit E 100. Sci Pharm 80:487-496.
16. Draize JH, Woodard G, Calvery HO. 1944. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 82:377-390.
17. Zimmer AK, Chetoni P, Saettone MF, Zerbe H, Kreuter J. 1995. Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye. II. Co-administration with bioadhesive and viscous polymers. J Control Release 33:31-46.
18. Stjernschantz J, Astin M. 1993. Anatomy and physiology of the eye. Physiological aspects of ocular drug therapy. In Biopharmaceutics of ocular drug delivery; Edman P, Ed. Boca Raton, Florida: CRC Press, pp 1-25.
19. Quinteros DA, Manzo RH, Allemandi DA. 2011. Interaction between Eudragit® E100 and anionic drugs: Addition of anionic polyelectrolytes and their influence on drug release performance. J Pharm Sci 100(11):4664-4673.
20. Govindarajan R, Nagarsenker MS. 2005. Formulation studies and in vivo evaluation of a flurbiprofen-hydroxypropyl beta-cyclodextrin system. Pharm Dev Technol 10(1):105-114.
21. Halim MA, Mahmoud AA. 2011. Formulation of indomethacin eye drops via complexation with cyclodextrins. Curr Eye Res 36(3):208-216.
22. Ishiguro T, Morishita E, Iohara D, Hirayama F, Wada K, Motoyama K, Arima H, Uekama K. 2011. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative. Int J Pharm 419(1-2):161-169.
23. Camber O. 1985. An in vitro model for determination of drug permeability through the cornea. Acta Pharm Suec 22:335-342.
24. Muchtar S, Abdulrazik M, Pery JF, Benita S. 1997. Ex-vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea. J Control Release 44:55-64.
25. Yang SC, Benita S. 2000. Enhanced absorption and drug targeting by positively charged submicron emulsions. Drug Develop Res 50:476-486.
26. Baydoun L, Furrer P, Gurny R, Muller-Goymann CC. 2004. New surface-active polymers for ophthalmic formulations: Evaluation of ocular tolerance. Eur J Pharm Biopharm 58:169-175.
27. Jimenez-Kairuz, AF, Allemandi, DA, Manzo, RH. 2003. Equilibrium properties and mechanism of kinetic release of metoclopramide from carbomer hydrogels. Int J Pharm 250:129-136.
28. Brewster M, Loftsson T. 2007. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59:645-666.
29. Cirri M, Maestrelli F, Orlandini S, Furlanetto S, Pinzauti S, Mura P. 2005. Determination of stability constant values of flurbiprofen-cyclodextrin complexes using different techniques. J Pharm Biomed Anal 37:995-1002.
30. Fialho SL, Cunha SA. 2004. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol 32:626-63225.
31. Tiffany JM. 2006. Surface tension in tears. Arch Soc Esp Oftalmol 81:363-366.
32. Dillen K, Vandervoort J, Van denMooter G, Ludwig A. 2006. Evaluation of ciprofloxacin-loaded eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm 314:72-82.
33. Palena MC, García MC, Manzo RH, JimenezKairuz A. 2012. Self-organized nanoparticles based on drug-interpolyelectrolyte complexes loading with acidic drugs. 2°. Reunión Internacional de Ciencias Farmacéuticas RICiFa, 2012. (CD of summaries-poster presentation) Rosario, Argentina.
34. Ishikawa Y, Aoki N, Ohshima H. 2005. Characterization of latex particles for aqueous polymeric coating by electroacoustic method. Colloids Surf B Biointerfaces 46:147-151.
35. Alasino RV, Leonhard V, Bianco ID, Beltramo DM. 2012. Eudragit E100 surface activity and lipid interactions. Colloids Surf B Biointerfaces 91:84-89.
36. Alasino SF, Ausar ID, Bianco LF, Castagna M, Contigiani RV, Beltramo DM. 2005. Amphipathic and membrane-destabilizing properties of the cationic acrylate polymer Eudragit E100. Macromol Biosci 5:207-213.
37. Alasino RV, Bianco ID, Vitali MS, Zarzur JA, Beltramo DM. 2007. Characterization of the inhibition of enveloped virus infectivity by the cationic acrylate polymer Eudragit E100. Macromol Biosci 7:1132-1138.
38. Ramirez-Rigo MV, Olivera ME, Rubio M, Manzo RH. 2014. Enhanced intestinal permeability and oral bioavailability of enalapril maleate upon complexation with the cationic polymethacrylate Eudragit E100. Eur J Pharm Sci 55:1-11.
39. Romero VL, Pons P, Bocco JL, Manzo RH, Alovero FL. 2012. Eudragit E100 potentiates the bactericidal action of ofloxacin against fluoroquinolone-resistant Pseudomonas aeruginosa. FEMS Microbiol Lett 334:102-110.